H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Alnylam Pharmaceuticals on Monday, setting a price target of $225, which is approximately 72.11% above the present share price of $130.73.
Trucchio expects Alnylam Pharmaceuticals to post earnings per share (EPS) of -$1.56 for the fourth quarter of 2020.
The current consensus among 11 TipRanks analysts is for a Strong Buy rating of shares in Alnylam Pharma (NASDAQ:ALNY), with an average price target of $174.7.
The analysts price targets range from a high of $225 to a low of $145.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $103.96 million and a net profit of -$198.86 million. The company's market cap is $15.19 billion.
According to TipRanks.com, H.C. Wainwright analyst Patrick Trucchio is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 3.2% and a 43.18% success rate.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp (OTC:SHCAY) on June 14, 2002 and is headquartered in Cambridge, MA.